NKTX

Nkarta, Inc.

5.34 USD
-0.16 (-2.91%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Nkarta, Inc. stock is down -18.35% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 June’s closed higher than May.

About Nkarta, Inc.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens.